IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund

IDEXX Laboratories surged 20.2% in Monday’s regular session, trading around $662.55 as of 1:54 PM ET, after a third-quarter earnings beat and raised full-year guidance. The stock later held near $662.27. The company, an S&P 500 component, gained visibility in broad index funds but the day’s impact depended on each investor’s holdings and weights. IDEXX reported GAAP EPS of $4.01, versus $3.716 expected, and revenue of $1.214B ahead of $1.192B consensus, up 9.9% year over year. Management now projects 2026 revenue of $4.741B to $4.767B and EPS of $14.96 to $15.16, with margin pressure reflecting acquisition costs tied to CoVet.